Trial · NCT07885410
PERCE-MUCO: Perceptions and Expectations of People With Cystic Fibrosis Regarding a Change in Treatment
NCT07885410, Recruiting, Fondation Ildys
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. PERCE-MUCO: Perceptions and Expectations of People With Cystic Fibrosis Regarding a Change in Treatment. Trials, record NCT07885410. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07885410
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- PERCE-MUCO: Perceptions and Expectations of People With Cystic Fibrosis Regarding a Change in Treatment
- NCT number
- NCT07885410
- Status
- Recruiting
- Enrollment
- 343 participants, estimated
- Lead sponsor
- Fondation Ildys
- Conditions
- Cystic Fibrosis (CF)
- First posted
- 2026-10-21
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Intention to switch from ETI to VTD | Day 1, (single assessment). | Percentage of participants selecting each of three responses to the question: 'If your physician offered VTD tomorrow, what would your position be?' Response options: immediate acceptance; need time to think; refusal. Report proportions and 95% confidence intervals |
| Secondary | Factors influencing willingness to switch | Day 1 | Descriptive proportions for knowledge of VTD and satisfaction with information received; preferred information sources; expectations; concerns about efficacy, adverse effects, replacing a satisfactory treatment and tolerability; and perceived access to treatment |
| Secondary | Correlation between quality of life and intention to switch | CFQ-R 14+ measurement closest to inclusion, collected from routine care | Correlation between the Quality of life measured by the CFQ-R 14+ scores, and the three-category intention-to-switch outcome ( immediate acceptance; need time to think; refusal). CFQ-R14+ scores explored 9 Quality of life domains (Physical, role/school, vitality, emotion, social, body image, eating, treatment burden, health perceptions) and 3 symptom scales. Each item is summed to generate a domain score and standardized. Scores range from 0 to 100, with higher scores indicating better health. |
| Secondary | Correlation between treatment adherence and intention to switch | Morisky-8 measurement closest to inclusion, collected from routine care | Correlaton between treatment adherence measured by Morisky score and three-category intention to switch outcome ( immediate acceptance; need time to think; refusal) ; adherence categories measured by Morisky score are good (score 8), medium (6-7) and low (\<6); |
| Secondary | Relationship between reported ETI tolerability and intention to switch | Adverse effects documented in the medical record and available at inclusion | Comparison of intention-to-switch categories ( immediate acceptance; need time to think; refusal) according to the presence or absence of adverse effects documented in the medical record |
| Secondary | Need for support during a potential treatment transition | Day 1 | Percentage of participants requesting specific support during transition and descriptive summary of requested support, including support from a physician, coordinating nurse or advanced practice nurse |
| Secondary | Patient perceptions and barriers identified in semi-structured interviews | One semi-structured interview of approximately 30-45 minutes during the study period. | Thematic analysis of interview transcripts exploring lived experience of Kaftrio, perception of therapeutic innovation, decision-making and the role of the advanced practice nurse |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07885410
GET https://conductscience.org/api/trials/v1/NCT07885410/registered